I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FILED VIA THE ELECTRONIC FILING SYSTEM, ON:

<u></u>	March 21, 2008
/Anita J. Galo/	March 21, 2008
SIGNATURE	DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zee Upton et al.

Serial No. : 10/565,616

Filing Date : June 9, 2006

For : SKIN REGENERATION SYSTEM

Art Unit : 1636

Confirmation No. : 2998

Examiner : TBD

Attorney Docket : FAK-8011

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria. VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

- 1. Pursuant to 37 CFR §1.97 and §1.98, and in compliance with CFR §1.56, the Office's attention is directed to the patents, pending applications, publications and other information listed on the attached PTO-1449. Applicant(s) make no admission that the documents are prior art to the present invention.
- 2. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a corresponding U.S. Patent is enclosed, or an English abstract, or a concise explanation of the relevance of the document is set forth on an attached sheet.
- 3. Pursuant to 37 CFR §1.97(b) this Statement is being filed (one must be checked):
 - (a) Within three months of the filing date or date of entry into the National Stage.
 - (b) Before the mailing date of a first Office Action on the merits.

	(c)	(c) 📙	but before the mailing date of either a final action or a notice of allowance or an action that otherwise closes prosecution in the application.			
			1)		A certification is given below,	
			2)		Enclosed is a check covering the fee (\$180.00) set forth in §1.17(p) for consideration of this Statement, or	
			3)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.	
	(d)		After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. The required certification and fee is indicated below.			
			1)		Enclosed is a check covering the fee set forth in 37 CFR §1.17(p) \$180, or	
			2)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.	
4.	Certification (if applicable):					
	(a)		The undersigned hereby certifies that each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.			
	(b)		The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the undersigned's knowledge after making reasonable inquiry no item of information contained in the Statement, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Statement.			
5.	The C	Commis	ssioner is hereby authorized to charge any additional fees,			

fees underpaid, or credit any overpayment with regard to this Statement to Deposit Account No. 20-0090.

Serial No. 10/565,616 Page -3-

6.	Canalaa	Evalenation	(if poodod):
0.	Concise	Explanation	(II Heeded).

(1) Below is a Concise Statement of Relevance of enclosed non-English language document(s).

OTHER DOCUMENTS

Schleicher et al., "Surface Modification by Complexes of Vitronectin and Growth Factors for Serum-Free Culture of Human Osteoblasts", *Tissue Engineering*, Vol. 11, No. 11-12, November 2005, pgs. 1688-1698, XP-009072079.

Kricker et al., "Structural and Functional Evidence for the Interaction of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins with Vitronectin", *Endocrinology*, Vol. 144, No. 7, July 2003, pgs. 2807-2815, XP-002398183.

Grant et al., "The Co-Application of Sprayed Cultured Autologous Keratinocytes and Autologous Fibrin Sealant in a Porcine Wound Model", *British Journal of Plastic Surgery*, Vol. 55, No. 3, April 2002, pages 219-227, XP-002398188.

Nam et al., "Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions", *Endorinology*, Vol. 143, No. 1, January 2002, pgs. 30-36.

Respectfully submitted,

/Richard S. Wesorick/

Richard S. Wesorick Reg. No. 40,871

TAROLLI, SUNDHEIM, COVELL, & TUMMINO L.L.P. 1300 East Ninth Street, Suite 1700 Cleveland, OH 44114

Phone: (216) 621-2234 Fax: (216) 621-4072 Customer No.: 26,294